【摘要】 本文报告我科1985年5月至1987年5月用EBVD方案治疗何杰金氏病20例和CEOP方案治疗非何杰金氏淋巴瘤27例的近期疗效和毒性反应。全组病例均经病理证实。何杰金氏病18例可评价疗效,CR8例(CR率44.4％),PR7例,(PR率38.9％)总有效率83.3％;非何杰金氏淋巴病23例可评价疗效,CR16例(CR率69.6％),PR7例(PR率30.4％),总有效率100％。 毒性反应,消化道反应多数较轻,不需治疗,白细胞下降不显著,4例因白细胞低合并感染,无死亡者;多数有脱发;未见肝肾功能异常;心电图异常者12次;未见心脏扩大或心衰者。 本文结果表明表阿霉素疗效与阿霉素相似,毒副作用较阿霉素轻。更多还原

【Abstract】 From May 1985 through May 1987, 20 cases of Hodgkin’s disease (HD) were treated with EBVD (Epirubicin, Bleomycin, Vincristine, Dacarbazine DTIC) combination chemotherapy, and 27 cases of non-Hodgkin lymphoma (NHL) were treated with CHOP (Cyclophos-phamide, Epirubicin, Vincristine, Prednison) combination chemotherapy. All the cases were histologically proved.18 cases of HD were evaluable for response. 8 cases achieved complete remission (CR rate 44.4%) and 7 partial remission(PR, 38.9%) total response rate were 83.3%. 23 cases of NHL were evaluable for response , 16 cases achieved CR<CR rate 69.6%) and 7 PR.(30.4%) total response rate 100%,side effect and toxicity were usually mild and reversible, with 4 cases of leucopenia and infection,all recovered following antibiotic treatment. No congestive heart failure or other severe toxicity and chemotherapy related death.These data suggested that in NHL comparable or even better response rate to CHOP treatment can be achieved with CEOP with less toxic side effects. However, in this study the therapeutic effect of EBVD regimen for HD was less satisfactory, the possible reasons were discussed.更多还原